We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Marker Linked to Aggressive Prostate Cancer

By HospiMedica staff writers
Posted on 29 May 2007
A recently identified genetic marker for prostate cancer is linked to a highly aggressive form of the disease. More...


This genetic marker ultimately will aid the development of a simple blood test to predict who is susceptible to this aggressive cancer. Knowing which patients carry this genetic marker also will guide doctors in how they treat the cancer.

A study, performed by Northwestern University's Feinberg School of Medicine (Chicago, IL, USA) investigators, showed a strong hereditary component to this aggressive cancer. Prostate cancer patients who carry the genetic marker--called 8q24--are much more likely to have a close family member with the disease. They have a 40% chance of having a close family member with prostate cancer. In contrast, prostate cancer patients who do not carry the marker have a 20% chance.

The study looked at more than 550 prostate cancer patients who had been treated at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. Researchers wanted to identify the characteristics of prostate cancer in men who were carriers of these genetic markers to see if their cancer differed from that in men who did not carry the gene variant.

"We found the carriers of these 8q24 markers had more aggressive tumors,” said Prof. Helfand, an assistant research professor of urology at Northwestern's Feinberg School of Medicine, a co-principal investigator of the study and a physician at Northwestern Memorial Hospital. "Patients who were carriers had cancers that were more likely to spread into the lymph nodes and were more difficult to surgically remove.”

Dr. Helfand presented his findings on May 20, 2007, at the American Urological Association meeting in Anaheim, CA, USA.


Related Links:
Northwestern University's Feinberg School of Medicine

Gold Member
Neonatal Heel Incision Device
Tenderfoot
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Wound Irrigation Solution
Prontosan®
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.